Protalex, Inc. is a biotechnology company focused on developing innovative therapies for autoimmune diseases. The company specializes in creating treatments that target specific immune system pathways, aiming to improve patient outcomes and quality of life. Founded in 2008, Protalex is based in New Jersey and has been working on its lead product candidate, PRTX-100, which is designed to treat conditions like rheumatoid arthritis. The company is committed to advancing its research and clinical trials to bring new options to patients suffering from these chronic illnesses.